MEDICINES DEVELOPMENT FOR GLOBAL HEALTH LIMITED

Overview

Medicines Development for Global Health Limited is a UK-registered charity (Charity number: 1200620) that focuses on the development of medicines for neglected diseases affecting low- and middle-income countries. The organization is part of a broader initiative to address significant health disparities globally.

Mission and Activities

The mission of Medicines Development for Global Health Limited is centered on researching, developing, and delivering medicines that address critical unmet medical needs in global health. Their primary activities include applying for funding, project managing clinical trials, particularly in Africa, and researching the causes, prevention, or cure of diseases. The charity also conducts research into existing and potential new medicines and vaccines, with a strong emphasis on developing these treatments for diseases that are often overlooked by traditional pharmaceutical companies.

Financial Overview

For the financial year ending June 30, 2023, the charity reported a total income of £350,268 and total expenditure of £288,667. The organization does not have trading subsidiaries, and none of its trustees receive remuneration.

Governance

The charity is overseen by a board of trustees, who are responsible for strategic decision-making and ensuring that the organization's activities align with its mission. There are no employees with total benefits exceeding £60,000 within the charity.

Relationship with Other Entities

While Medicines Development for Global Health Limited is registered in the UK, it is affiliated with Medicines Development for Global Health (MDGH), a not-for-profit pharmaceutical company based in Melbourne, Australia. MDGH is known for its work in developing affordable medicines and vaccines for neglected diseases.

Impact

Medicines Development for Global Health Limited contributes to the broader efforts of MDGH by supporting clinical trials and research into neglected diseases. Their work helps address the health disparities faced by millions in low- and middle-income countries. One notable achievement associated with MDGH is the development of moxidectin, a novel treatment for river blindness (onchocerciasis), marking the first new treatment for this condition in 20 years.

[1] https://www.medicinesdevelopment.com [2] https://www.ntd-ngonetwork.org/medicines-development-for-global-health [3] https://www.acnc.gov.au/charity/charities/4d240789-38af-e811-a960-000d3ad24282/profile [4] https://aamri.org.au/members/affiliates/medicines-development-for-global-health/ [5] https://register-of-charities.charitycommission.gov.uk/charity-details/?regId=1200620&subId=0